Supriya Lifescience Ltd shared an investor presentation highlighting a 24% revenue increase to ₹1,932.1 million for 9M FY25 and a 33% increase to ₹659.5 million for Q3 FY25 compared to the previous year with notable growth in EBITDA and PAT margins.
AI Assistant
Supriya Lifescience Ltd
2025
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.